Abbott Laboratories (NY:ABT)

97.50 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

58 59 Next >

Want Decades of Passive Income? 2 Stocks to Buy Now. ↗

March 22, 2024

There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.

Via The Motley Fool

3 Stocks to Buy Right Now for the Coming Recession ↗

March 21, 2024

With numerous economic indicators souring, these three stocks to buy for a recession will protect your portfolio's downside.

Via InvestorPlace

Topics Economy

3 Resilient Stocks to Protect Your Wealth During a Recession ↗

March 21, 2024

Discover three recession-resistant stocks with growth leads in the consumer staples, household products, and healthcare industries.

Via InvestorPlace

Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)

March 20, 2024

Via AB Newswire

Topics Death

What the Options Market Tells Us About Abbott Laboratories ↗

March 19, 2024

Via Benzinga

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗

March 08, 2024

Via Benzinga

Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now? ↗

March 07, 2024

Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy?

Via The Motley Fool

Exploring ABBOTT LABORATORIES (NYSE:ABT)s quality characteristics. ↗

March 05, 2024

Why the quality investor may take a look at ABBOTT LABORATORIES (NYSE:ABT).

Via Chartmill

What's Going On With Abbott Laboratories Stock On Friday? ↗

March 15, 2024

An Illinois jury orders Reckitt Benckiser's Mead Johnson to pay $60 million after a premature infant's tragic death linked to Enfamil baby formula. Mead Johnson found negligent for not warning about...

Via Benzinga

Topics Lawsuit

Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst ↗

March 15, 2024

Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil.

Via Investor's Business Daily

Topics Death

SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster ↗

March 13, 2024

With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors.

Via InvestorPlace

Topics ETFs

Medtronic is a Dividend Aristocrat That Keeps Gaining

March 11, 2024

A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector

Via MarketBeat

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗

March 01, 2024

Via Benzinga

Could Abbott Laboratories Stock Help You Become a Millionaire? ↗

February 26, 2024

Abbott's earnings have soared over the past decade.

Via The Motley Fool

Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning

February 23, 2024

Via Investor Brand Network

3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March ↗

March 11, 2024

These are some of the best-performing stocks in what's arguably society's most important industry.

Via The Motley Fool

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's ↗

March 06, 2024

FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant...

Via Benzinga

3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates ↗

March 06, 2024

These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns.

Via InvestorPlace

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment ↗

February 23, 2024

Via Benzinga

Peering Into Abbott Laboratories's Recent Short Interest ↗

February 20, 2024

Via Benzinga

Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win ↗

March 06, 2024

The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it.

Via Investor's Business Daily

Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite ↗

March 03, 2024

There is a world of opportunities ahead for this healthcare giant.

Via The Motley Fool

Nearing Retirement? These Stocks Are as Cautious as They Come ↗

February 28, 2024

Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.

Via The Motley Fool

3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade ↗

February 27, 2024

These stocks don't offer the highest yields, but their payouts are growing fast.

Via The Motley Fool

3 Blue-Chip Stocks to Buy to Bolster Your Portfolio ↗

February 26, 2024

Delve into three undervalued blue-chip stocks to buy driving growth in consumer staples, pharmaceuticals, and healthcare.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 26, 2024

Via Benzinga

Looking for Growth? 7 Hot Trends That Have Been Flying Under Investors’ Radar. ↗

February 26, 2024

Discover 7 under-the-radar stock trends set to make waves in the stock market. Find out why savvy investors are tuning in.

Via InvestorPlace

Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth ↗

February 23, 2024

Explore recession-proof stocks thriving in Energy, Health Care, Industrials, and more, offering stability and growth amid economic turmoil.

Via InvestorPlace

Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade ↗

February 21, 2024

In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday.

Via Investor's Business Daily

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.